Combination of a PD-1 antagonist and a 4-1BB agonist for treating cancer
US10899840B2 · kind B2 · utility
2Cited by
13References
11Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Feb 3, 2015 |
| Grant date | Jan 26, 2021 |
| Priority date | — |
| Expiry date | Feb 3, 2035 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/76
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present disclosure describes combination therapies comprising an antagonist of Programmed Death 1 receptor (PD-1) and a selective 4-1 BB agonist, and the use of the combination therapies for the treatment of cancer, and in particular for treating cancers that express PD-L1.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.